Theravance Biopharma (NASDAQ:TBPH) Issues Quarterly Earnings Results

Theravance Biopharma (NASDAQ:TBPH) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26), Zacks reports. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million for the quarter, compared to the consensus estimate of $29.90 million.

Theravance Biopharma Trading Up 1.2 %

Shares of NASDAQ:TBPH traded up $0.11 on Friday, reaching $9.38. 62,259 shares of the company’s stock were exchanged, compared to its average volume of 208,689. Theravance Biopharma has a twelve month low of $7.44 and a twelve month high of $10.90. The company has a fifty day moving average of $9.34 and a 200-day moving average of $8.92. The company has a market capitalization of $461.25 million, a price-to-earnings ratio of -9.29 and a beta of 0.21.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 309,565 shares in the company, valued at $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.